Skip to content
OpenCapital
Earnings
Screener
Charts
Portfolio
Pricing
Connect your AI
Get started
Toggle navigation menu
Stocks
Kura Oncology
Business Segments
Products & Services
Research And Development Expense
Research And Development Expense
Kura Oncology
·
Products & Services
·
3 segments
·
Rolls up to
R&D
Breakdown
Segments
Ziftomenib
View metric
Darlifarnib
View metric
Discovery Stage Program
View metric
Quarterly
Annual
TTM
Segment
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Ziftomenib
$29.95M
$37.58M
$40.32M
$34.73M
$36.88M
Darlifarnib
—
—
$8.49M
$6.84M
$6.57M
Discovery Stage Program
$2.09M
$1.49M
$1.74M
$1.91M
$1.4M
Total
$55.97M
$62.79M
$67.91M
$64.41M
$65.26M